Evaluation of endothelial function and estimation of the degree of apoptosis in patients with metabolic syndrome and non-alcoholic fatty liver disease

Om, Drapkina; Deeva, T. A.; Vt, Ivashkin

doi:10.17116/terarkh201587576-83

Cited by 14 publications

(5 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Обнаружены корреляции между концентрацией галектина-3, с одной стороны, и стеатозом печени и поджелудочной железы, шкалой риска фиброза при НАЖБП (NAFLD fibrosis score), ИБС, ХСН, фракцией фиброза сердца -с другой. Таким образом, галектин-3 может быть фактором прогрессирования фиброза не только в печени, но и в миокарде [23].…”

Section: неалкогольная жировая болезнь печени и сердечно-сосудистые зunclassified

Continuum of non-alcoholic fatty liver disease: from hepatic steatosis to cardiovascular risk

Drapkina¹,

Корнеева²

2016

Racionalʹnaâ farmakoterapiâ v kardiologii

Self Cite

View full text Add to dashboard Cite

Государственный научно-исследовательский центр профилактической медицины 101990, Москва, Петроверигский пер., 10 стр.3 Рассматривается проблема неалкогольной жировой болезни печени (НАЖБП), являющейся независимым фактором риска ряда сердечно-сосудистых заболеваний (ССЗ). Продемонстрирована высокая распространенность сердечно-сосудистых факторов риска в российской популяции больных НАЖБП. Детально рассматриваются общие патофизиологические механизмы НАЖБП с ССЗ (инсулинорезистентность и избыточное накопление липидов в печени). У пациентов с НАЖБП наряду с большей распространенностью традиционных факторов риска развития ССЗ (ожирение, сахарный диабет, метаболический синдром и др.) встречаются «новые» факторы риска (увеличение толщины перикардиального жира, эндотелиальная дисфункция, утолщение комплекса интима-медиа, повышение уровня С-реактивного белка в крови и др.). Рассматриваются взаимосвязь НАЖБП с атеросклерозом, дислипидемиями, особенности метаболизма желчных кислот при НАЖБП и возможности воздействия на эти компоненты.

show abstract

Section: неалкогольная жировая болезнь печени и сердечно-сосудистые зunclassified

Continuum of non-alcoholic fatty liver disease: from hepatic steatosis to cardiovascular risk

Drapkina¹,

Корнеева²

2016

Racionalʹnaâ farmakoterapiâ v kardiologii

Self Cite

View full text Add to dashboard Cite

show abstract

“…This condition, along with cardiovascular diseases and metabolic disturbances in lipid and carbohydrate metabolism associated with insulin resistance (IR) syndrome, is gaining increased attention. NAFLD covers a broad range of metabolic liver damages in the context of IR, including simple fatty liver (steatosis), steatosis with inflammation and liver cell damage (nonalcoholic steatohepatitis, NASH), and fibrosis, which can evolve into cirrhosis of the liver [3,4].…”

Section: Introductionmentioning

confidence: 99%

The Contribution of Non-Alcoholic Fatty Liver Disease to the Progression of Atherosclerosis

Sadikova,

Khodjaeva

2024

tajmspr

View full text Add to dashboard Cite

In the context of insulin resistance syndrome, which encompasses changes in lipid and carbohydrate metabolism, liver-related issues are now being closely examined alongside cardiovascular diseases. Our research aimed to evaluate the predictive importance of non-alcoholic fatty liver disease (NAFLD) for identifying the likelihood of early atherosclerotic alterations in the carotid arteries. We discovered a connection between NAFLD and initial signs of atherosclerosis. By ranking prognostic factors that affect changes in the carotid artery wall, we've been able to develop a method for estimating individual atherosclerosis risk in people who are otherwise healthy. The practical value of our findings underscores the need for in-depth evaluation of individuals with NAFLD to identify risk factors that may contribute to the advancement of both liver and cardiovascular diseases.

show abstract

“…Васкулоэндотелиальный фактор роста при воспалительном процессе активирует выработку коллагена звёздчатыми клетками печени и механизмы неоангиогенеза. В ряде исследований, проведенных на крысах со стеатозом, было показано, что ЭД возникает еще до начала воспаления и развития фиброза в печени [4,6,7,8].…”

Section: Introductionunclassified

The importance of vascular endothelial growth factor and polymorphism of the VEGF a gene (g634c) in the development of steatosis, fibrosis and cirrhosis of the liver patients in the city of Perm

Булатова

Shevlyukova

Щекотова

et al. 2023

jour

View full text Add to dashboard Cite

Introduction. Chronic liver diseases are a significant medical problem all over the world. To date, there is a need to develop a set of laboratory tests, including genetic ones, to determine the risk of development and progression of steatosis, fibrosis and cirrhosis of the liver of various etiologies. Aim: To investigate the serum concentration of vasculoendothelial growth factor (VEGF) and the frequency of occurrence of VEGFA gene polymorphism genotypes in the region -634G/C (rs2010963) in patients with steatosis, fibrosis and cirrhosis of the liver in the Perm Region. Materials and methods: 258 people were examined, including 52 patients with non-alcoholic liver steatosis, 95 patients with chronic hepatitis C and liver fibrosis, 46 people with cirrhosis of the liver of viral (HCV) and alcoholic etiology and 65 practically healthy individuals. The serum concentration of VEGF was determined by enzyme immunoassay. Polymorphisms of the VEGFA gene in region -634G/C were analyzed by polymerase chain reaction. Result: The development of steatosis, fibrosis and cirrhosis of the liver is accompanied by endothelial damage with activation of neoangiogenesis due to hyperproduction of VEGF (p=0.001, p=0.0001 and p=0.001, respectively) in the blood serum. Elevated serum VEGF values in patients confirmed the presence of endothelial dysfunction in liver pathology. The study of the single nucleotide polymorphism of the VEGFA gene (G634C) showed a higher incidence of recessive allele C in patients with steatosis and cirrhosis in 54.81% (p=0.01) and 48.9% (p=0.04) of cases than in the control group -37.69%, which suggested the presence of an association of the carrier of allele C of this polymorphism in the form of genotypes CC or GC with a risk of developing steatosis and cirrhosis of the liver. Conclusion. Determination of the genetic marker VEGFA in the region -634G/C allows us to assess the increased risk of developing chronic liver diseases when exposed to various etiological factors.

show abstract

Evaluation of endothelial function and estimation of the degree of apoptosis in patients with metabolic syndrome and non-alcoholic fatty liver disease

Cited by 14 publications

References 19 publications

Continuum of non-alcoholic fatty liver disease: from hepatic steatosis to cardiovascular risk

Continuum of non-alcoholic fatty liver disease: from hepatic steatosis to cardiovascular risk

The Contribution of Non-Alcoholic Fatty Liver Disease to the Progression of Atherosclerosis

The importance of vascular endothelial growth factor and polymorphism of the VEGF a gene (g634c) in the development of steatosis, fibrosis and cirrhosis of the liver patients in the city of Perm

Contact Info

Product

Resources

About